Metropolitan Life Insurance Co. NY increased its position in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 18.1% during the 2nd quarter, HoldingsChannel reports. The fund owned 20,739 shares of the biotechnology company’s stock after purchasing an additional 3,177 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Heron Therapeutics were worth $806,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HRTX. Wells Fargo & Company MN boosted its position in shares of Heron Therapeutics by 86.6% during the 1st quarter. Wells Fargo & Company MN now owns 60,545 shares of the biotechnology company’s stock worth $1,670,000 after acquiring an additional 28,095 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Heron Therapeutics by 14.7% during the 1st quarter. Rhumbline Advisers now owns 49,228 shares of the biotechnology company’s stock worth $1,359,000 after acquiring an additional 6,322 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Heron Therapeutics during the 1st quarter worth approximately $183,000. State Board of Administration of Florida Retirement System boosted its position in shares of Heron Therapeutics by 12.6% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 19,010 shares of the biotechnology company’s stock worth $525,000 after acquiring an additional 2,131 shares in the last quarter. Finally, Swiss National Bank boosted its position in shares of Heron Therapeutics by 1.8% during the 1st quarter. Swiss National Bank now owns 100,300 shares of the biotechnology company’s stock worth $2,768,000 after acquiring an additional 1,800 shares in the last quarter.

A number of brokerages have weighed in on HRTX. Zacks Investment Research upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating and set a $43.00 target price on the stock in a research report on Wednesday, July 18th. BidaskClub lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Cantor Fitzgerald restated a “buy” rating and issued a $40.00 target price on shares of Heron Therapeutics in a research report on Thursday, June 21st. ValuEngine upgraded shares of Heron Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 2nd. Finally, Cowen restated a “buy” rating and issued a $54.00 target price on shares of Heron Therapeutics in a research report on Thursday, June 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the company’s stock. Heron Therapeutics has a consensus rating of “Buy” and a consensus target price of $50.50.

In other news, VP Kimberly Manhard sold 6,000 shares of the firm’s stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $37.53, for a total transaction of $225,180.00. Following the completion of the transaction, the vice president now owns 6,000 shares of the company’s stock, valued at $225,180. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kevin C. Tang sold 2,695,000 shares of the firm’s stock in a transaction on Wednesday, September 12th. The shares were sold at an average price of $35.75, for a total transaction of $96,346,250.00. The disclosure for this sale can be found here. Insiders have sold 3,085,469 shares of company stock valued at $111,612,708 in the last ninety days. Insiders own 16.20% of the company’s stock.

Shares of Heron Therapeutics stock opened at $31.65 on Tuesday. Heron Therapeutics Inc has a fifty-two week low of $14.40 and a fifty-two week high of $42.90.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.14. The firm had revenue of $17.28 million for the quarter, compared to analyst estimates of $12.82 million. Heron Therapeutics had a negative net margin of 411.41% and a negative return on equity of 112.35%. The company’s quarterly revenue was up 103.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.80) earnings per share. sell-side analysts expect that Heron Therapeutics Inc will post -2.2 EPS for the current year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Further Reading: Stock Symbols Definition, Examples, Lookup

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.